Cargando…
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339938/ https://www.ncbi.nlm.nih.gov/pubmed/32650143 http://dx.doi.org/10.1016/j.jns.2020.117011 |
| _version_ | 1783554961437622272 |
|---|---|
| author | Bollo, Luca Guerra, Tommaso Bavaro, Davide Fiore Monno, Laura Saracino, Annalisa Angarano, Gioacchino Paolicelli, Damiano Trojano, Maria Iaffaldano, Pietro |
| author_facet | Bollo, Luca Guerra, Tommaso Bavaro, Davide Fiore Monno, Laura Saracino, Annalisa Angarano, Gioacchino Paolicelli, Damiano Trojano, Maria Iaffaldano, Pietro |
| author_sort | Bollo, Luca |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7339938 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73399382020-07-07 Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide Bollo, Luca Guerra, Tommaso Bavaro, Davide Fiore Monno, Laura Saracino, Annalisa Angarano, Gioacchino Paolicelli, Damiano Trojano, Maria Iaffaldano, Pietro J Neurol Sci Letter to the Editor Elsevier B.V. 2020-09-15 2020-07-04 /pmc/articles/PMC7339938/ /pubmed/32650143 http://dx.doi.org/10.1016/j.jns.2020.117011 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Bollo, Luca Guerra, Tommaso Bavaro, Davide Fiore Monno, Laura Saracino, Annalisa Angarano, Gioacchino Paolicelli, Damiano Trojano, Maria Iaffaldano, Pietro Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide |
| title | Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide |
| title_full | Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide |
| title_fullStr | Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide |
| title_full_unstemmed | Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide |
| title_short | Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide |
| title_sort | seroconversion and indolent course of covid-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339938/ https://www.ncbi.nlm.nih.gov/pubmed/32650143 http://dx.doi.org/10.1016/j.jns.2020.117011 |
| work_keys_str_mv | AT bolloluca seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide AT guerratommaso seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide AT bavarodavidefiore seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide AT monnolaura seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide AT saracinoannalisa seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide AT angaranogioacchino seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide AT paolicellidamiano seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide AT trojanomaria seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide AT iaffaldanopietro seroconversionandindolentcourseofcovid19inpatientswithmultiplesclerosistreatedwithfingolimodandteriflunomide |